» Articles » PMID: 39907913

Chinese Expert Consensus on Clinical Management of Hepatopathy-related Thrombocytopenia (2023 Edition)

Overview
Journal Hepatol Int
Publisher Springer
Date 2025 Feb 5
PMID 39907913
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatopathy-related thrombocytopenia refers to a reduction in platelet count caused by liver disease or its treatment. The incidence of this condition is correlated with the duration and severity of liver disease. The direct impact of thrombocytopenia on the clinical outcome of patients with liver disease is an increased risk of bleeding. In addition, the indirect effect involves delays or discontinuation of treatment due to the potential risk of bleeding. The pathophysiological mechanisms of hepatopathy-related thrombocytopenia include reduced platelet production, abnormal distribution, increased destruction or consumption, and so on. Current treatment strategies targeting different mechanisms include thrombopoietic agents, surgery, immunosuppressants, and platelet transfusion. However, their clinical application lacks standardization. The National Clinical Research Center for Infectious Diseases organized experts to discuss and develop this consensus to enhance the clinical management level of hepatopathy-related thrombocytopenia in China. The experts focused on aspects of diagnosis, classification, and choosing the best treatment plans based on the most recent research in the field.

References
1.
Gangireddy V, Kanneganti P, Sridhar S, Talla S, Coleman T . Management of thrombocytopenia in advanced liver disease. Can J Gastroenterol Hepatol. 2014; 28(10):558-64. PMC: 4234356. DOI: 10.1155/2014/532191. View

2.
Huang C, Chang J, Wu Y, Huang S, Chen W, Hsu C . Different impacts of common risk factors associated with thrombocytopenia in patients with hepatitis B virus and hepatitis C virus infection. Biomed J. 2021; 45(5):788-797. PMC: 9661505. DOI: 10.1016/j.bj.2021.09.001. View

3.
Li Q, He M, Chen H, Fang W, Zhou Y, Xu L . Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. J Clin Oncol. 2021; 40(2):150-160. DOI: 10.1200/JCO.21.00608. View

4.
Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N . Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol. 2018; 3(6):424-432. DOI: 10.1016/S2468-1253(18)30078-5. View

5.
Peck-Radosavljevic M . Thrombocytopenia in chronic liver disease. Liver Int. 2016; 37(6):778-793. DOI: 10.1111/liv.13317. View